Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ropeginterferon alfa-2b versus anagrelide in high-risk essential thrombocythemia after hydroxyurea resistance or intolerance
CTR20200195Phase 3Active
- Sponsor
- Pyramid Laboratories, Inc.
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ropeginterferon alfa-2b, anagrelide in thrombocythemia, sponsored by Pyramid Laboratories, Inc.. Started Nov 2020; status: active.
02
Drugs
ropeginterferon alfa-2banagrelide
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on CTR20200195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200195.